AtriCure, Inc. (ATRC) Stock Analysis
Range Bound setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Momentum 4.2/10 is below the 5.0 floor at $27.30 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Below 200-MA, MA slope -2.5%/30d (confirmed downtrend); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3).
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and... Read more
Sell if holding. Momentum 4.2/10 is below the 5.0 floor at $27.30 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Below 200-MA, MA slope -2.5%/30d (confirmed downtrend); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3). Chart setup: RSI 40 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — AtriCure, Inc.
Latest news
- NEWS AtriCure stock hits 52-week low at $27.04 By Investing.com - Investing.com Australia — Investing.com Australia negative
- NEWS AtriCure (NASDAQ:ATRC) Reaches New 52-Week Low - What's Next? - MarketBeat — MarketBeat negative
- NEWS AtriCure stock hits 52-week low at $27.04 - Investing.com — Investing.com negative
- NEWS AtriCure, Inc. (NASDAQ:ATRC) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat — MarketBeat positive
- NEWS Here's What Key Metrics Tell Us About AtriCure (ATRC) Q1 Earnings - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 4.2/10 is below the 5.0 floor at $27.30 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Below 200-MA, MA slope -2.5%/30d (confirmed downtrend); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3). Chart setup: RSI 40 mid-range, Bollinger mid-band. Prior stop was $25.39. Score 5.3/10, moderate confidence.
Take-profit target: $40.89 (+49.8% upside). Prior stop was $25.39. Stop-loss: $25.39.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3); Below 200-MA, MA slope -2.5%/30d (confirmed downtrend); Value-trap signals (2/5): Margin compression (op margin 0.4%), Material insider selling (3 sells, 0.03% of cap).
AtriCure, Inc. trades at a P/E of N/A (forward 77.2). TrendMatrix value score: 7.5/10. Verdict: Sell.
16 analysts cover ATRC with a consensus score of 4.1/5. Average price target: $47.
What does AtriCure, Inc. do?AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue,...
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.